Lead Sponsor

Strados Labs, Inc.

Age

35 - 75 years

Sex

ALL

Healthy Volunteers

No

•1. Males and females between the ages of 35 and 75 with documented physician-diagnosed COPD
•2. Hospitalization with a primary diagnosis of COPD with exacerbation or pneumonia.
•3. Patient able and willing to provide informed consent.
•4. Patient can follow study procedures, including instructions for self-placement and operation of device
•a. Patient has experience using a smartphone
•5. Accessible by telehealth/telephone upon discharge
•6. Patient is able and willing to return to study site for study follow-up visits as necessary

•1. Patient unable or unwilling to provide informed consent
•2. Diagnosis of COPD is uncertain
•3. Plan for discharge to location other than the patient's home (eg, Nursing Home, Rehabilitation facility)
•4. Patient with end-stage medical condition with expected survival no more than 3 months
•5. History of adverse reaction or allergy to TegaDerm®
•6. Inaccessible by telehealth/telephone post discharge

Related studies

NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07509606 · Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration

NCT07451977 · Chronic Respiratory Failure, Hypoxemia, and more

NCT07082738 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07477600 · Chronic Obstructive Pulmonary Disease (COPD)

Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD